Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with chemotherapy and surgery within its marketing authorisation for treatment of resectable gastric or gastro-oesophageal junction cancer.
Please note that following on from information provided to NICE by the company in July 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 2696
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 November 2024 | Discontinued. Please note that following on from information provided to NICE by the company in July 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 18 July 2023 | Suspended. For information, the company have announced that KEYNOTE 585 trial met one of its three primary endpoints and they will not be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 16 June 2023 | Note added to the project documents |
| 09 May 2023 | Note - Note added to the project documents |
| 30 March 2023 | Note added to the project documents |
| 01 July 2021 - 29 July 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 June 2021 | Note added to the project documents |
| 24 January 2020 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual